Alla Volyanska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alla Volyanska has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Igor Z. Gladchuk
Odesa national medical university, Odesa
3 shared publications - Анастасія С. Лунько
Odesa National Medical University, Odesa, Ukraine
2 shared publications - Dmytro Zhelezov
Одеський національний медичний університет
1 shared publication - G. L. Lavrynenko
Odesa national medical university, Odesa
1 shared publication - Liudmyla Berlinska
Odesa National Medical University Odesa Ukraine
1 shared publication O.S. Salekh
Одеський національний медичний університет, м. Одеса, Ukraine
1 shared publication
Latest Publications
- Open Access
- 28 May 2026
- Published by Ternopil State Medical University in Актуальні питання педіатрії, акушерства та гінекології
- No. 1,p. 4-9
КЛІНІЧНА ХАРАКТЕРИСТИКА ЖІНОК З ЕНДОМЕТРІОЗАСОЦІЙОВАНИМ БЕЗПЛІДДЯМ
Мета дослідження – оцінити клініко-анамнестичну картину пацієнток з ендометріозасоційованим безпліддям. Матеріали та методи. Дослідження проведено на базі Науково-клінічного центру ендометріозу ІІІ рівня акредитації Європейської ліги ендометріозу (Багатопрофільний медичний центр Одеського національного медичного університету) у 2023–2024 рр. Обстежено 95 безплідних пацієнток репродуктивного віку з ендоскопічно верифікованим генітальним ендометріозом (ГЕ). Результати дослідження та їх обговорення. Середній вік пацієнток склав (31,5±3,0) року. Первинне безпліддя було діагностовано у 61 (64,71 %) пацієнтки, вторинне – у 34 (35,29 %). Тривалість безплідного періоду в деяких випадках сягала 8 років і в середньому склала (4,57±1,32) року. У кожної другої пацієнтки тривалість безпліддя перебувала у межах 3–5 років – 54 (57,35 %). У пацієнток із тривалістю безпліддя <3 років показники кількості антральних фолікулів (правий яєчник – 8,8±0,50, лівий яєчник – 7,2±0,40) та товщини М-ехо (9,6±1,2) відповідали збереженій оваріальній функції. Найбільш виражені порушення встановлено у жінок із безпліддям понад 5 років, що супроводжувалося майже двократним зменшенням кількості антральних фолікулів (3,9±0,36 і 3,1±030) та зниженням товщини М-ехо (7,6±1,5) (p<0,001). У групі жінок із тривалістю безплідного періоду <3 років переважали пацієнтки з І–ІІ стадіями ГЕ за r-ASRM (40,00 та 25,00 % відповідно). Найбільш несприятливий перебіг захворювання спостерігали у пацієнток із тривалістю безплідного періоду понад 5 років, у яких домінували двобічні ендометріоми (47,62 %) та тяжкі форми спайкового процесу органів малого таза (28,57 та 42,86 % відповідно). Аналіз особливостей ендометріоїдного ураження яєчників показав, що при безплідді <3 років у всіх групах домінували однобічні ендометріоми (81,82 %), однак при тривалості безплідного періоду понад 5 років частіше діагностували двобічне ураження яєчників (до 16,37 %). Спайковий процес ОМТ І–ІІ ступенів (18,52 і 14,81 %) частіше реєстрували у пацієнток із коротшою тривалістю безпліддя, тоді як при тривалості безпліддя понад 5 років частіше діагностували ІІІ–IV ступені (9,26 %) адгезивного ураження ОМТ. Висновки. Збільшення тривалості безплідного періоду (більше 5 років) можна вважати одним із прогностично несприятливих критеріїв при оцінці репродуктивного потенціалу в жінок з ендометріозасоційованим безпліддям.
- 28 May 2026
- Published by Ternopil State Medical University in Актуальні питання педіатрії, акушерства та гінекології
- No. 1,p. 4-9
Open AccessКЛІНІЧНА ХАРАКТЕРИСТИКА ЖІНОК З ЕНДОМЕТРІОЗАСОЦІЙОВАНИМ БЕЗПЛІДДЯМ
Мета дослідження – оцінити клініко-анамнестичну картину пацієнток з ендометріозасоційованим безпліддям. Матеріали та методи. Дослідження проведено на базі Науково-клінічного центру ендометріозу ІІІ рівня акредитації Європейської ліги ендометріозу (Багатопрофільний медичний центр Одеського національного медичного університету) у 2023–2024 рр. Обстежено 95 безплідних пацієнток репродуктивного віку з ендоскопічно верифікованим генітальним ендометріозом (ГЕ). Результати дослідження та їх обговорення. Середній вік пацієнток склав (31,5±3,0) року. Первинне безпліддя було діагностовано у 61 (64,71 %) пацієнтки, вторинне – у 34 (35,29 %). Тривалість безплідного періоду в деяких випадках сягала 8 років і в середньому склала (4,57±1,32) року. У кожної другої пацієнтки тривалість безпліддя перебувала у межах 3–5 років – 54 (57,35 %). У пацієнток із тривалістю безпліддя <3 років показники кількості антральних фолікулів (правий яєчник – 8,8±0,50, лівий яєчник – 7,2±0,40) та товщини М-ехо (9,6±1,2) відповідали збереженій оваріальній функції. Найбільш виражені порушення встановлено у жінок із безпліддям понад 5 років, що супроводжувалося майже двократним зменшенням кількості антральних фолікулів (3,9±0,36 і 3,1±030) та зниженням товщини М-ехо (7,6±1,5) (p<0,001). У групі жінок із тривалістю безплідного періоду <3 років переважали пацієнтки з І–ІІ стадіями ГЕ за r-ASRM (40,00 та 25,00 % відповідно). Найбільш несприятливий перебіг захворювання спостерігали у пацієнток із тривалістю безплідного періоду понад 5 років, у яких домінували двобічні ендометріоми (47,62 %) та тяжкі форми спайкового процесу органів малого таза (28,57 та 42,86 % відповідно). Аналіз особливостей ендометріоїдного ураження яєчників показав, що при безплідді <3 років у всіх групах домінували однобічні ендометріоми (81,82 %), однак при тривалості безплідного періоду понад 5 років частіше діагностували двобічне ураження яєчників (до 16,37 %). Спайковий процес ОМТ І–ІІ ступенів (18,52 і 14,81 %) частіше реєстрували у пацієнток із коротшою тривалістю безпліддя, тоді як при тривалості безпліддя понад 5 років частіше діагностували ІІІ–IV ступені (9,26 %) адгезивного ураження ОМТ. Висновки. Збільшення тривалості безплідного періоду (більше 5 років) можна вважати одним із прогностично несприятливих критеріїв при оцінці репродуктивного потенціалу в жінок з ендометріозасоційованим безпліддям.
- Open Access
- 13 February 2026
- Published by Professional Event, LLC in Reproductive health of woman
- No. 1,p. 58-63
The symptom-modifying effect of dienogest in patients with genital endometriosis who have proliferative changes in the mammary glands
Modern studies show that in different countries 15–70% of patients with genital endometriosis (GE) have concomitant breast pathology, which is considered a manifestation of overlap syndrome. This category of patients requires a detailed examination of the mammary glands when choosing hormonal therapy, as well as more careful observation during treatment.The objective: to assess the symptom-modifying effect of dienogest in patients with GE who have proliferative changes in the mammary glands.Materials and methods. 226 women of reproductive age with GE were examined. Staging of endometriosis was performed according to the revised version of the American Society of Reproductive Medicine classification after laparoscopic intervention. Diagnosis, treatment and clinical monitoring of patients were carried out in compliance with modern bioethical requirements, as well as in accordance with the recommendations of the World Health Organization and the American College of Obstetricians and Gynecologists. All patients had ultrasound examination of the mammary glands. Changes in functional status were assessed using the Breast imaging reporting and data system (BI-RADS) scale. Endopain questionnaire was used to determine the intensity of pain syndrome in GE. As a symptom-modifying drug, patients were prescribed dienogest 2 mg once a day for 24 weeks. The presence of clinical manifestations of GE was determined before and after treatment.Results. Proliferative changes in the tissues of the mammary gland were detected in 65.6% of the examined patients with GE. As the stage of endometriosis progresses, the severity of proliferative changes in the mammary glands increases (positive correlation of medium strength with the stage of external GE was found, r = 0.53; p < 0.05). In the selected cohort of patients, the use of dienogest 2 mg for 6 months led to a decrease in the intensity, and in many cases to the disappearance of chronic pelvic pain syndrome and other manifestations of the disease: algodysmenorrhea and dyspareunia.Conclusions. The study confirmed the world data that the overlap syndrome of GE and dyshormonal breast diseases is a common clinical phenomenon. It has been established that with increasing stage of endometriosis, there is an increase in the breast pathologies frequency. In the treatment of patients with overlap syndrome of GE and dyshormonal breast diseases, the effectiveness of dienogest has been confirmed, as evidenced by the regression of clinical symptoms of GE, in particular, a decrease in the intensity of chronic pelvic pain syndrome. It is important that hormonal therapy for endometriosis has demonstrated a high safety profile, because it not only does not provoke the occurrence of side effects, but also does not have an undesirable effect on the functional state of the mammary glands.
- 13 February 2026
- Published by Professional Event, LLC in Reproductive health of woman
- No. 1,p. 58-63
Open AccessThe symptom-modifying effect of dienogest in patients with genital endometriosis who have proliferative changes in the mammary glands
Modern studies show that in different countries 15–70% of patients with genital endometriosis (GE) have concomitant breast pathology, which is considered a manifestation of overlap syndrome. This category of patients requires a detailed examination of the mammary glands when choosing hormonal therapy, as well as more careful observation during treatment.The objective: to assess the symptom-modifying effect of dienogest in patients with GE who have proliferative changes in the mammary glands.Materials and methods. 226 women of reproductive age with GE were examined. Staging of endometriosis was performed according to the revised version of the American Society of Reproductive Medicine classification after laparoscopic intervention. Diagnosis, treatment and clinical monitoring of patients were carried out in compliance with modern bioethical requirements, as well as in accordance with the recommendations of the World Health Organization and the American College of Obstetricians and Gynecologists. All patients had ultrasound examination of the mammary glands. Changes in functional status were assessed using the Breast imaging reporting and data system (BI-RADS) scale. Endopain questionnaire was used to determine the intensity of pain syndrome in GE. As a symptom-modifying drug, patients were prescribed dienogest 2 mg once a day for 24 weeks. The presence of clinical manifestations of GE was determined before and after treatment.Results. Proliferative changes in the tissues of the mammary gland were detected in 65.6% of the examined patients with GE. As the stage of endometriosis progresses, the severity of proliferative changes in the mammary glands increases (positive correlation of medium strength with the stage of external GE was found, r = 0.53; p < 0.05). In the selected cohort of patients, the use of dienogest 2 mg for 6 months led to a decrease in the intensity, and in many cases to the disappearance of chronic pelvic pain syndrome and other manifestations of the disease: algodysmenorrhea and dyspareunia.Conclusions. The study confirmed the world data that the overlap syndrome of GE and dyshormonal breast diseases is a common clinical phenomenon. It has been established that with increasing stage of endometriosis, there is an increase in the breast pathologies frequency. In the treatment of patients with overlap syndrome of GE and dyshormonal breast diseases, the effectiveness of dienogest has been confirmed, as evidenced by the regression of clinical symptoms of GE, in particular, a decrease in the intensity of chronic pelvic pain syndrome. It is important that hormonal therapy for endometriosis has demonstrated a high safety profile, because it not only does not provoke the occurrence of side effects, but also does not have an undesirable effect on the functional state of the mammary glands.
- Open Access
- 20 November 2025
- Published by Publishing House Zaslavsky in EMERGENCY MEDICINE
- Vol. 21 (7) , 725-730
The effectiveness of iron deficiency nutritional correction in patients with genital endometriosis accompanied by mild anemia
Background. Women with endometriosis are at higher risk of developing iron deficiency than those without endometriosis. The results of many studies indicate that iron deficiency should be considered during the initial diagnosis and subsequent treatment of endometriosis, since menstrual disorders with the simultaneous presence of endometrioid heterotopias are one of the factors for the development of anemia in women. The purpose was to study the effectiveness of nutritional correction of iron deficiency in patients with genital endometriosis accompanied by dysmenorrhea. Materials and methods. Endometriosis patients with mild anemia were prescribed nutritional correction of iron deficiency. In the study group (n = 34), women received a complex of microencapsulated iron pyrophosphate (14 mg) in liposomal form with folic acid (200 μg), vitamin B12 (2.5 μg) and vitamin C (80 mg), as well as a dietary supplement of lactoferrin at a dose of 250 mg per day for 2 months; in the comparison group (n = 32), the above-mentioned combination drug was administered without adding lactoferrin to the diet. The patients were assessed for the following indicators: hemoglobin level, erythrocyte count, ferritin levels, transferrin and total serum iron concentration before treatment and after 2 months. Results. Nutritional correction of iron deficiency in patients with endometriosis accompanied by mild anemia with the use of a complex of iron pyrophosphate and vitamins is not only effective, but also safe, because no side effects of diet therapy were recorded. Adding the dietary supplement lactoferrin to the iron-vitamin preparation improves restoration of the iron metabolism level and normalizes its key indicators: hemoglobin, ferritin and serum iron, and leads to a more significant increase in transferrin. It is also important that the mean corpuscular hemoglobin concentration in the study group reached normal, while in the comparison group, it only approached normal values. Conclusions. Lactoferrin in combination with an iron-vitamin complex can provide the most favorable conditions for the absorption of the required amount of iron against the background of a decrease in the inflammation and normalization of the microbiota. Due to its affinity for transferrin, lactoferrin participates in the full restoration of the proper level of iron metabolism, which is consistent with the data of other studies in recent years.
- 20 November 2025
- Published by Publishing House Zaslavsky in EMERGENCY MEDICINE
- Vol. 21 (7) , 725-730
Open AccessThe effectiveness of iron deficiency nutritional correction in patients with genital endometriosis accompanied by mild anemia
Background. Women with endometriosis are at higher risk of developing iron deficiency than those without endometriosis. The results of many studies indicate that iron deficiency should be considered during the initial diagnosis and subsequent treatment of endometriosis, since menstrual disorders with the simultaneous presence of endometrioid heterotopias are one of the factors for the development of anemia in women. The purpose was to study the effectiveness of nutritional correction of iron deficiency in patients with genital endometriosis accompanied by dysmenorrhea. Materials and methods. Endometriosis patients with mild anemia were prescribed nutritional correction of iron deficiency. In the study group (n = 34), women received a complex of microencapsulated iron pyrophosphate (14 mg) in liposomal form with folic acid (200 μg), vitamin B12 (2.5 μg) and vitamin C (80 mg), as well as a dietary supplement of lactoferrin at a dose of 250 mg per day for 2 months; in the comparison group (n = 32), the above-mentioned combination drug was administered without adding lactoferrin to the diet. The patients were assessed for the following indicators: hemoglobin level, erythrocyte count, ferritin levels, transferrin and total serum iron concentration before treatment and after 2 months. Results. Nutritional correction of iron deficiency in patients with endometriosis accompanied by mild anemia with the use of a complex of iron pyrophosphate and vitamins is not only effective, but also safe, because no side effects of diet therapy were recorded. Adding the dietary supplement lactoferrin to the iron-vitamin preparation improves restoration of the iron metabolism level and normalizes its key indicators: hemoglobin, ferritin and serum iron, and leads to a more significant increase in transferrin. It is also important that the mean corpuscular hemoglobin concentration in the study group reached normal, while in the comparison group, it only approached normal values. Conclusions. Lactoferrin in combination with an iron-vitamin complex can provide the most favorable conditions for the absorption of the required amount of iron against the background of a decrease in the inflammation and normalization of the microbiota. Due to its affinity for transferrin, lactoferrin participates in the full restoration of the proper level of iron metabolism, which is consistent with the data of other studies in recent years.
- Open Access
- 29 September 2023
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 69,p. 95-103
Theranostics of uterine leiomyoma: present and future
Research objectives: to develop an algorithm for predicting the growth of uterine fibrodis, taking into account the state of epigenetic regulation. Materials and methods. The study was conducted on the basis of clinical divisions of the Department of Obstetrics and Gynecology in 2018–2021. 28 patients with uterine fibroids were examined. Expression of miRNA-29b and miRNA-146a in tumor tissue was determined in all women using real-time PCR. Obtained data were analyzed using the statistical program Statistica 10.0 (StatSoft Inc., USA). Results. The average age of the patients was 39.3 ± 1.0 years. The average number of nodes was 2.7 ± 0.4. The expression levels of microRNA-29b were most frequently determined in the range of 2–7 units and microRNA-146a in the range of 30–67 units in most of the examined tissue samples. The expression of miRNA-29b has the greatest significance for the growth forecast (Wald statistic). According to the logistic regression equation the prognostic factors are patient’s age, estradiol and progesterone level in the I and II phases of the menstrual cycle, diameter of the largest node, expression of miRNA-29b and miRNA-146a. Conclusions. This study shows that the use of miRNA expression profile as an additional marker in the diagnosis and treatment of uterine fibroids is promising and requires more detailed research. Further study of the correlation of clinical and paraclinical parameters can make it possible to predict the course of uterine fibroids, and therefore to apply an effective personalized treatment plan. Theranostics is a new approach to the diagnosis and treatment of patients, based on the uniqueness of each person in order to choose the optimal treatment strategy against the background of the molecular genetic technologies, in particular to determine epigenetic changes in hyperproliferative diseases. The study of miRNA expression may find its place in the theranostics of uterine fibroids in the future.
- 29 September 2023
- Published by Publishing Office TRILIST in Reproductive Endocrinology
- No. 69,p. 95-103
Open AccessTheranostics of uterine leiomyoma: present and future
Research objectives: to develop an algorithm for predicting the growth of uterine fibrodis, taking into account the state of epigenetic regulation. Materials and methods. The study was conducted on the basis of clinical divisions of the Department of Obstetrics and Gynecology in 2018–2021. 28 patients with uterine fibroids were examined. Expression of miRNA-29b and miRNA-146a in tumor tissue was determined in all women using real-time PCR. Obtained data were analyzed using the statistical program Statistica 10.0 (StatSoft Inc., USA). Results. The average age of the patients was 39.3 ± 1.0 years. The average number of nodes was 2.7 ± 0.4. The expression levels of microRNA-29b were most frequently determined in the range of 2–7 units and microRNA-146a in the range of 30–67 units in most of the examined tissue samples. The expression of miRNA-29b has the greatest significance for the growth forecast (Wald statistic). According to the logistic regression equation the prognostic factors are patient’s age, estradiol and progesterone level in the I and II phases of the menstrual cycle, diameter of the largest node, expression of miRNA-29b and miRNA-146a. Conclusions. This study shows that the use of miRNA expression profile as an additional marker in the diagnosis and treatment of uterine fibroids is promising and requires more detailed research. Further study of the correlation of clinical and paraclinical parameters can make it possible to predict the course of uterine fibroids, and therefore to apply an effective personalized treatment plan. Theranostics is a new approach to the diagnosis and treatment of patients, based on the uniqueness of each person in order to choose the optimal treatment strategy against the background of the molecular genetic technologies, in particular to determine epigenetic changes in hyperproliferative diseases. The study of miRNA expression may find its place in the theranostics of uterine fibroids in the future.
- Open Access
- 1 May 2023
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 20 (3) , em473
The model of screening for preeclampsia in the second and third trimesters of gestation
Purpose: Preeclampsia (PE) is a specific syndrome of multiple organ insufficiency in case of pregnancy, which is included in the panel of major obstetric syndromes and is among the main causes of maternal morbidity and mortality in the whole world. Material and methods: We conducted a prospective cohort study of 91 pregnant women to evaluate the effectiveness of integrated use of maternal risk factors (2019 International Federation of Gynecology and Obstetrics recommendations), placenta location (ultrasound at 18-20 weeks of gestation), and serum cystatin C (at 18-36 weeks of gestation) in screening for pe in the second and third trimesters of gestation. Results: In the subgroup of pregnant women with cystatin C levels greater than 1.0 mg/L (27 women), PE developed in 26 women, which is 96.29% in percentage terms. When calculating GFR for cystatin C in a group with PE there was a significant violation of the renal filtration system -52.46±2.08 (95% CI, 48.39-56.54), while in healthy group the indicator is within normal limits -97.6±1.64 (95% CI, 94.38-100.82). In the analysis of the ratio of cystatin C levels more than 1.0 mg / l and the development of PE, a sensitivity of 98.46%, specificity of 100% and accuracy of 98.9%, p<0.001. Conclusions: The data show that the combined model of maternal factors, ultrasound of the placenta and serum cystatin C, is prognostically effective in pregnant women in the second and third trimesters of gestation and is a reliable marker for the development of pe.
- 1 May 2023
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 20 (3) , em473
Open AccessThe model of screening for preeclampsia in the second and third trimesters of gestation
Purpose: Preeclampsia (PE) is a specific syndrome of multiple organ insufficiency in case of pregnancy, which is included in the panel of major obstetric syndromes and is among the main causes of maternal morbidity and mortality in the whole world. Material and methods: We conducted a prospective cohort study of 91 pregnant women to evaluate the effectiveness of integrated use of maternal risk factors (2019 International Federation of Gynecology and Obstetrics recommendations), placenta location (ultrasound at 18-20 weeks of gestation), and serum cystatin C (at 18-36 weeks of gestation) in screening for pe in the second and third trimesters of gestation. Results: In the subgroup of pregnant women with cystatin C levels greater than 1.0 mg/L (27 women), PE developed in 26 women, which is 96.29% in percentage terms. When calculating GFR for cystatin C in a group with PE there was a significant violation of the renal filtration system -52.46±2.08 (95% CI, 48.39-56.54), while in healthy group the indicator is within normal limits -97.6±1.64 (95% CI, 94.38-100.82). In the analysis of the ratio of cystatin C levels more than 1.0 mg / l and the development of PE, a sensitivity of 98.46%, specificity of 100% and accuracy of 98.9%, p<0.001. Conclusions: The data show that the combined model of maternal factors, ultrasound of the placenta and serum cystatin C, is prognostically effective in pregnant women in the second and third trimesters of gestation and is a reliable marker for the development of pe.